The Food and Drug Administration (FDA) has accepted a supplemental Biologics License Application to treat Opdivo (nivolumab) in patients with stage 2B or 2C melanoma that has been completely resected (surgically removed), according to Bristol Myers Squibb, the manufacturer of the immunotherapy agent.
Scientific Publications
A 47-Year-Old Woman with Metastatic Melanoma
Hussein Tawbi, MD, PhD: Hello. My name is Hussein Tawbi. I’m a melanoma medical oncologist at MD Anderson Cancer Center. I’m professor and deputy chair of the Department of Melanoma Medical Oncology and co-director of the Brain Metastasis Clinic here at MD Anderson Cancer Center. What we’re discussing today is a case of an unfortunate lady in her 40s, specifically a 47-year-old lady who presented with a 2.2-millimeter primary melanoma of the skin of her left thigh.
FDA Grants Orphan Drug Designation to LNS8801 for Metastatic Cutaneous Melanoma
The FDA has granted orphan drug designation for LNS8801 for the treatment of patients with metastatic cutaneous melanoma, according to Linnaeus Therapeutics, Inc.
Immune Checkpoint Inhibitors and CVD Risk in Patients With Melanoma
Immune checkpoint inhibitor (ICI) therapy may increase the risk of major atherosclerotic cardiovascular events (MACE) in patients with high-risk or advanced melanoma, according to a study published in Cardio-Oncology.